



1624
#5
8/13/02
SN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Varney et al.

Serial No.: 10/047,935 ✓

Filed: October 23, 2001 ✓

For: ANTIPROLIFERATIVE
SUBSTITUTED 5-THIAPYRIMIDINONE
AND 5-SELENOLYRIMIDINONE
COMPOUNDS ✓

Group Art Unit: 1624

Examiner: Not yet assigned

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

AUG 06 2002

TECH CENTER 1600-2901

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. §1.56 and in accordance with the practice under 37 C.F.R. §§1.97 (b) (3) and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. The documents are being cited because they were cited previously in Applicant's parent applications, or are U.S. patents that issued from the copending U.S. applications cited in Applicants' parent applications.

In conformity with CFR §1.98(d), copies of the listed documents are not enclosed. This application is a divisional of 09/782,284, filed February 14, 2001, now U.S. Patent No. 6,323,210, which is a divisional of U.S. Patent Application No. 09/588,654, filed June 7, 2000, now U.S. Patent No. 6,207,670, which is a divisional of U.S. Patent Application No. 09/307,595, filed May 10, 1999, now abandoned, which is a divisional of U.S. Patent Application No. 09/003,163, filed January 6, 1998, now U.S. Patent No. 5,945,427, which is a divisional of U.S. Patent Application No. 08/448,556, filed June 7, 1995, now U.S. Patent No. 5,739,141, which is a 371 of International Application No. PCT/US93/11795, filed December 10, 1993, which is a continuation-in-part of U.S.

CERTIFICATE OF MAILING
(37 C.F.R. §1.8(A))

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

7/25/02

Date of Deposit

Robert Prince

Name of Person Mailing Paper

Robert Prince

Signature of Person Mailing Paper

Patent Application No. 07/991,259, filed December 16, 1992, now abandoned. The Examiner is respectfully invited to review the parent applications for such documents. Of course, if the Examiner wishes Applicants to provide additional copies of the cited U.S. patent, Applicants will gladly forward such copies upon receipt of a request to do so.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

It is believed that no fees are due for consideration of this Information Disclosure Statement. The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-0622.

Respectfully submitted,



Robert Prince
Registration No. 38,583

Agouron Pharmaceuticals, Inc./A Pfizer Company
10350 North Torrey Pines Road
La Jolla, Ca 92037
(858) 622-8817